These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11037799)

  • 21. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.
    Bagheri A; Kamalidehghan B; Haghshenas M; Azadfar P; Akbari L; Sangtarash MH; Vejdandoust F; Ahmadipour F; Meng GY; Houshmand M
    Drug Des Devel Ther; 2015; 9():2627-34. PubMed ID: 25999696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
    Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
    Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
    Hendset M; Molden E; Knape M; Hermann M
    Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2D6 genotyping in patients on psychoactive drug therapy.
    Topić E; Stefanović M; Ivanisević AM; Blazinić F; Culav J; Skocilić Z
    Clin Chem Lab Med; 2000 Sep; 38(9):921-7. PubMed ID: 11097351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
    Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
    Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
    Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
    Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
    Raimundo S; Toscano C; Klein K; Fischer J; Griese EU; Eichelbaum M; Schwab M; Zanger UM
    Clin Pharmacol Ther; 2004 Aug; 76(2):128-38. PubMed ID: 15289790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
    Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
    Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype.
    Chida M; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T
    Pharmacogenetics; 1999 Jun; 9(3):287-93. PubMed ID: 10471060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Madsen H; Hansen TS; Brøsen K
    Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
    Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
    Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.
    Marez D; Legrand M; Sabbagh N; Lo Guidice JM; Spire C; Lafitte JJ; Meyer UA; Broly F
    Pharmacogenetics; 1997 Jun; 7(3):193-202. PubMed ID: 9241659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction.
    Stüven T; Griese EU; Kroemer HK; Eichelbaum M; Zanger UM
    Pharmacogenetics; 1996 Oct; 6(5):417-21. PubMed ID: 8946473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.
    Evert B; Eichelbaum M; Haubruck H; Zanger UM
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):309-18. PubMed ID: 9089660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
    Daly AK; Leathart JB; London SJ; Idle JR
    Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
    Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
    Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.